Sintx Technologies, Inc. (SINT)
| Market Cap | 11.60M -2.6% |
| Revenue (ttm) | 1.33M -28.5% |
| Net Income | -18.00M |
| EPS | -4.60 |
| Shares Out | 6.66M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 43,710 |
| Open | 1.770 |
| Previous Close | 1.770 |
| Day's Range | 1.690 - 1.780 |
| 52-Week Range | 1.400 - 4.500 |
| Beta | 0.59 |
| Analysts | Strong Buy |
| Price Target | 9.25 (+431.61%) |
| Est. Earnings | Nov 12, 2026 |
About SINT
Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. The company offers monolithic solid silicon nitride; solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyether ether ketone, and Polyether Ether Ketone (PEE). The company was formerly known as Amedica Cor... [Read more]
Financial Performance
In 2025, Sintx Technologies's revenue was $1.02 million, a decrease of -64.74% compared to the previous year's $2.89 million. Losses were -$17.08 million, 55.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for SINT stock is "Strong Buy." The 12-month stock price target is $9.25, which is an increase of 431.61% from the latest price.
News
Sintx Technologies reports preliminary Q3 revenue $2.2M
Sintx Technologies (SINT) announced preliminary, unaudited revenue of $2.2M for the third quarter ended September 30, 2026. The result exceeds the high end of the Company’s previously announced guidan...
SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance
Third-quarter revenue grows roughly 380% from Q2, driven by stronger-than-expected industrial sales to Fortune 500 customers; Company reiterates Q4 revenue guidance Revenue milestone also enables Com...
SINTX Technologies Announces Silicon Nitride Masterclass with Leading Orthopedics Experts
Experts in implant retrieval, biomaterials and clinical practice examine the science, clinical experience and potential advantages of silicon nitride relative to established implant materials in Compa...
SINTX Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference
SALT LAKE CITY, Utah, Sept. 08, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company commercializing proprietary s...
Sintx Technologies files to sell 1.27M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.27M shares of common stock. The company is not selling any…
SINTX Technologies Regains Compliance with Nasdaq Stockholders' Equity Requirement
SALT LAKE CITY, Utah, Aug. 13, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a company focused on advanced silicon nitride materials and medical technolo...
Sintx Technologies Registration statement: Registration filing
Sintx Technologies filed a registration statement on August 13, 2026, providing details about a securities offering with the SEC.
Sintx Technologies Earnings Call Transcript: Q2 2026
Q2 2026 saw a 199% revenue increase and improved gross margins, driven by contract manufacturing and initial commercialization of the SINAPTIC wedge system. Liquidity remains a concern despite recent financing, with guidance for continued revenue growth but significant execution risks.
Sintx Technologies Quarterly report: Q2 2026
Sintx Technologies has published its Q2 2026 quarterly earnings report on August 11, 2026.
Sintx Technologies Earnings release: Q2 2026
Sintx Technologies released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
SINTX Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth Initiatives
SALT LAKE CITY, Utah, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride biomaterials and ceramics for medical a...
SINTX Technologies Announces Second Quarter 2026 Earnings Release Date and Webcast
SALT LAKE CITY, Utah, July 28, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride ceramics and advanced material technolo...
SINTX Technologies Engages Veteran MedTech Executive Chris Lyons and Southern Metrics to Establish Strategic Opportunity Management Program
SALT LAKE CITY, Utah, July 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced biomaterials and silicon nitride technologies for medic...
Sintx Technologies Registration statement: Registration filing
Sintx Technologies filed a registration statement on June 25, 2026, providing details about a securities offering with the SEC.
Sintx Technologies files to sell 5.82M shares of common stock for holders
06:03 EDT Sintx Technologies (SINT) files to sell 5.82M shares of common stock for holders
Sintx Technologies receives $3.2M in purchase orders
Sintx Technologies (SINT) announced that it has received purchase orders from multiple contract manufacturing customers with an aggregate value exceeding $3.2M for the production of advanced ceramic c...
SINTX Technologies Announces Receipt of More Than $3.2 Million in Contract Manufacturing Purchase Orders
SALT LAKE CITY, Utah, June 22, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride ceramics and advanced material technolo...
Sintx Technologies Transcript: Transcript
Silicon nitride implants offer superior infection resistance and bone integration, targeting the fast-growing extremities market with FDA-cleared foot and ankle products. Strong surgeon adoption, robust IP, and strategic partnerships support a path to profitability within three years.
Sintx Technologies resumed with a Buy at Maxim
Maxim analyst Anthony Vendetti resumed coverage of Sintx Technologies (SINT) with a Buy rating and $6 price target
SINTX Technologies Announces Raise of Approximately $5.0 Million of Capital, Including a $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
SALT LAKE CITY, Utah, June 03, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced biomaterials company focused on developing silicon nitride techn...
SINTX Technologies to Present at the LD Micro Invitational XVI Conference
Salt Lake City, Utah--(Newsfile Corp. - May 17, 2026) - SINTX Technologies, Inc. (NASDAQ: SINT) ("SINTX" or the "Company"), a medical technology company focused on advanced ceramics and silicon nitrid...
Sintx Technologies initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Sintx Technologies (SINT) with a Buy rating and $10 price target Sintx is developing silicon nitride-based biomaterials, which offer a “differentiated combination...
SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution
Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026
Sintx Technologies announces first in-human surgery using FDA-cleared Sinaptic
The company states: “SINTX Technologies (SINT) announced the successful completion of the first-in-human surgical procedure utilizing its FDA-cleared SINAPTIC Foot & Ankle Osteotomy Wedge System, mark...
SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant
Major clinical milestone marks SINTX's entry into the foot and ankle reconstruction market and advances commercialization of its silicon nitride biomaterial platform